-
1Academic Journal
Συγγραφείς: Irina V. Fridman, Natalia A. Lyubimova, Mikhail M. Kostik, Susanna M. Kharit, Yulia E. Konstantinova, И. В. Фридман, Н. А. Любимова, М. М. Костик, С. М. Харит, Ю. Е. Константинова
Πηγή: Pediatric pharmacology; Том 18, № 5 (2021); 398-407 ; Педиатрическая фармакология; Том 18, № 5 (2021); 398-407 ; 2500-3089 ; 1727-5776
Θεματικοί όροι: ювенильный идиопатический артрит, live and non-live vaccines, immunosuppressive therapy, vaccine-induced antibodies survivability, vaccination safety, vaccination efficacy, rheumatological diseases, juvenile idiopathic arthritis, живые и неживые вакцины, иммуносупрессивная терапия, сохранность поствакцинальных антител, безопасность вакцинации, эффективность вакцинации, ревматологические заболевания
Περιγραφή αρχείου: application/pdf
Relation: https://www.pedpharma.ru/jour/article/view/2066/1306; Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi:10.1016/S0140-6736(07)60363-8; Hinks A, Ke X, Barton A, et al. Association of the IL2RA/ CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(1):251–257. doi:10.1002/art.24187; Yanagimachi M, Miyamae T, Naruto T, et al. Association of HLA-A and HLA-DRB1 with clinical subtypes of juvenile idiopathic arthritis. J Hum Genet. 2011;56(3):196–199. doi:10.1038/jhg.2010.159; Ombrello M, Remmers E, Tachmazidou I, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112(52):15970–15975. doi:10.1073/pnas.1520779112; Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669–679. doi:10.1093/rheumatology/kev382; Salvana E, Salata R. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009;22(2):274–290. doi:10.1128/CMR.00040-08; Atzeni F, Batticciotto A, Masala I, et al. Infections and Biological Therapy in Patients with Rheumatic Diseases. IMAJ. 2016;18(3–4): 164–167.; Hurd A, Beukelman Т. Infectious Complications in Juvenile Idiopathic Arthritis Current. Rheumatol Rep. 2013;15(5):327. doi:10.1007/s11926-013-0327-1; Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293. doi:10.1002/art.10524; Abinun M, Lane JP, Wood M, et al. Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis. Emerg Infect Dis. 2016;22(10):1720–1727. doi:10.3201/eid2210.151245; Harrison P. Antibiotics in Children Increase Risk for Juvenile Arthritis. Medscape Medical News. November 18, 2014. Available online: http://www.medscape.com/viewarticle/835110. Accessed on November 22, 2014.; Bongartz T, Sutton A, Sweeting M, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19): 2275–2278. doi:10.1001/jama.295.19.2275; Ringold S, Weiss P, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Rheum. 2013;65(10):2499–2512. doi:10.1002/art.38092; Bijl M, Agmon-Levin N, Dayer J, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11:572–576. doi:10.1016/j.autrev.2011.10.015; Намазова-Баранова Л.С., Валиева С.И., Федосеенко М.В. и др. Анализ вакцинального статуса у пациентов с ювенильным идиопатическим артритом // Педиатрическая фармакология. — 2016. — Т. 13. — № 4. — С. 334–330. doi:10.15690/pf.v13i4.1604; Toussirot E, Bereau M. Vaccination and Induction of Autoimmune Diseases. Inflamm Allergy Drug Targets. 2015;14(2):94–98. doi:10.2174/1871528114666160105113046; Groot N, Heijstek M, Wulffraat N. Vaccinations in Paediatric Rheumatology: an Update on Current Developments. Curr Rheumatol Rep. 2015;17:46. doi:10.1007/s11926-015-0519-y; Chalmers D, Scheifele C, Patterson D, Williams R. Immunization of Patients With Rheumatoid Arthritis Against Influenza: A Study of Vaccine Safety and Immunogenicity. J Rheumatol. 1994;21(7): 1203–1206.; Кощеева Ю.В., Харит С.М., Черняева Т.В. и др. Принципы формирования индивидуального графика прививок детям с ревматическими заболеваниями // Некоторые современные вопросы вакцинопрофилактики. — СПб.; 2000. — Т. 2. — С. 27–31.; Klotsche J, Niewerth M, Haas J, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75(5): 855–861. doi:10.1136/annrheumdis-annrheumdis-2014-206747; Horneff G, Seyger MMB, Arikan D, et al. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease. Pediatr. 2018;201:166–175.e3. doi:10.1016/j.jpeds.2018.05.042; Carvalho L, de Paula F, Silvestre R, et al. Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients. Pediatr Rheumatol. 2013;11:10. doi:10.1186/1546-0096-11-10; Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, et al. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589–594.; Woerner A, Sauvain MJ, Aebi C, et al. Immune response to influenza vaccination in children treated with methotrexate or/ and tumor necrosis factor-alpha inhibitors. Human Vaccines. 2011;7(12):1293–1298. doi:10.4161/hv.7.12.17981; DellEra L, Corona F, Daleno C, et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccinein children with juvenile idiopathic arthritis. Vaccine. 2012;30(5): 936–940. doi:10.1016/j.vaccine.2011.11.083; Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012;22(6): 871–876. doi:10.1007/s10165-012-0595-z; Toplak N, Subelj V, Kveder T, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(3): 436–444.; Heijstek M, Ott de Bruina L, Borrow R, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: A systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–122. doi:10.1016/j.autrev.2011.08.010; Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1): 39–52. doi:10.1136/annrheumdis-2019-215882; Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–173. doi:10.3899/jrheum.110721; Aikawa N, Campos L, Goldenstein-Schainberg C, et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Rheumatol. 2013;42(1):34–40. doi:10.3109/03009742.2012.709272; Буханова Д.В., Белов Б.С., Тарасова Г.М. и др. Эффективность, безопасность и иммуногенность трехвалентной инактивированной сплит-вакцины против гриппа у пациентов с ревматическими заболеваниями // Медицинский совет. — 2018. — № 12. — С. 106–110. doi:10.21518/2079-701X-2018-12-106-110; Костинов М.П., Тарасова A.A. Вакцинация детей с ревматическими заболеваниями // Эпидемиология и Вакцинопрофилактика. — 2016. — Т. 15. — № 3. — С. 101–105.; Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях: руководство для врачей. — М.: МДВ; 2009. — 252 с.; Kasapcopur O, Cullu F, Kamburoglu-Goksel A, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(9):1128–1130. doi:10.1136/ard.2003.013201; Nerome Y, Akaike H, Nonaka Y, et al. The safety and effectiveness of HBV vaccination in patients with juvenile idiopathic arthritis controlled by treatment. Mod Rheumatol. 2016;26(3):368–371. doi:10.3109/14397595.2015.1085608; Szczygielska I, Hernik E, Gazda A, et al. Assessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs, vaccinated against viral type B hepatitis in infancy. Reumatologia. 2020;58(1):15–20. doi:10.5114/reum.2020.93508; Maritsi D, Vartzelis G, Soldatou A, et al. Markedly decreased antibody titers against hepatitis B in previously immunised children presenting with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2013;31(6):969–973.; Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi:10.1016/j.vaccine.2010.03.080; Солошенко М.А., Алексеева Е.И., Бзарова Т.М. и др. Профилактика пневмококковой инфекции у детей с ювенильным идиопатическим артритом // Вопросы современной педиатрии. — 2017. — Т. 16. — (1): 24-28. doi:10.15690/vsp.v16i1.1691; Brunner HI, Tzaribachev N, Cornejo GV, et al. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol. 2020;18(1):1–7. doi:10.1186/s12969-020-0410-x; Heijstek М, van Gageldonk P., Berbers G. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–954. doi:10.1136/annrheumdis-2011-200637; Borte S, Liebert U, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology. 2009;48(2):144–148. doi:10.1093/rheumatology/ken436; Heijstek M, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449–2456. doi:10.1001/jama.2013.6768; Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine. 2009;27(37): 5041–5042. doi:10.1016/j.vaccine.2009.06.052; Любимова Н.А., Фридман И.В., Голева О.В. и др. Сохранность поствакцинального иммунитета против кори, краснухи, эпидемического паротита, гепатита В и дифтерии у пациентов с ювенильным идиопатическим артритом, планово иммунизированных в возрасте до 2 лет: предварительные результаты одномоментного исследования // Вопросы современной педиатрии. — 2019. — Т. 18. — № 6. — С. 435–441. doi:10.15690/vsp.v18i5.2063; Erguven M, Kaya B, Hamzah O, Tufan F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc. 2011;74(5):205–208. doi:10.1016/j.jcma.2011.03.004; Stoof S, Heijstek M, Sijssens K, et al. Kinetics of the longterm antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis. 2014;73(4):728–734. doi:10.1136/annrheumdis-2012-202561; Esposito S, Corona F, Barzon L, et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. Exp Review Vaccines. 2014;13(11):1387–1393. doi:10.1586/14760584.2014.943195; Heijstek M, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500–1507. doi:10.1136/annrheumdis-2013-203429; Pileggi G, de Souza C, Ferriani V. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken). 2010;62(7):1034–1039. doi:10.1002/acr.20183; Toplak N, Avčin T. Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy. Vaccine. 2015;33(33):4056–4059. doi:10.1016/j.vaccine.2015.06.086; https://www.pedpharma.ru/jour/article/view/2066